

HSC Technology Group – TGA for CardiacSense wearable

9 May 2022

HIGHLIGHTS

- **HSC receives TGA for the new CardiacSense Solution**
- **HSC approved to start marketing and sales in Australia and New Zealand**
- **HSC extending its Talius Platform into the broader healthcare market**

Further to the announcement in August 2020, **HSC Technology Group Ltd (HSC or the Company) (ASX:HSC)** is pleased to announce Therapeutic Goods Approval¹ (**TGA**) and the beginning of commercialisation of the CardiacSense solution.

The CardiacSense solution is a watch which has been developed from the ground up as an enterprise grade medical device for continuous measurement of heart rate and arrhythmias at ECG-level accuracy. The medical indications certified include “detection of Atrial Fibrillation (A-Fib), and monitoring of Heart Rate Variability (HRV), with continuous Photoplethysmography (PPG) and spot Electrocardiogram (ECG).

HSC Technology Group is the exclusive partner with CardiacSense in Australia and New Zealand following an extensive development process and clinical trials. HSC is the first and only company to receive TGA certification for continuous PPG wristband monitoring at the individual heartbeat level and arrhythmia detection, a milestone that will enable HSC to provide proactive health monitoring to the Australian and New Zealand market.

HSC Technology Group has integrated the Cardiac Sense data into the HSC Talius Platform to enable emergency response and remote patient monitoring, providing a key element for an end to end solution of 24hr support. HSC sees this new offering as a continuation of the Talius IoT data collection processing and the entry of HSC into the healthcare industry.

CardiacSense enables continuous long-term, accurate and comfortable patient monitoring without the need to implant invasive cardiac monitors - a prevalent experience for patients experiencing arrhythmias. Data from 2 clinical trials reviewed by the TGA demonstrated accurate detection of A-Fib by continuous PPG of over 99%. In parallel, CardiacSense has launched clinical trials to receive regulatory certification for additional vital signs including continuous respiratory rate, core temperature, oxygen saturation, blood pressure and other arrhythmias.

Commenting on the TGA, Mr. Graham Russell, Managing Director said:

“We are excited to bring this amazing solution to the market. Australia has an estimated 4 million people with hypertension. The addressable market and opportunity for HSC, in our view, is material. With over 60% undetected this is a simple and easy way for specialists and physicians to provide an easy to wear proactive solution and with the back-up of our Talius Platform, plus the 24hr response, we can offer the first end to end solution.”

¹ ARTG Number 387674

Mr. Russell added *"We have had significant interest from the Cardiology sector who have shared their excitement recognising this is also the first cost effective post treatment solution that will allow ongoing and continuous monitoring for their clients and the opportunity to provide better ongoing health outcomes.*

It also further demonstrates the flexibility and power of our Talius Platform which enables sensor data collection, analysis and presentation to the end user. We see CardiacSense as a natural evolution beyond our existing Aged Care focus and provides us further entry into the broader healthcare market."

This announcement has been authorised by the Board of Directors of HSC Technology Group Ltd.

Investor Enquiries:

Stephen Rodgers

Company Secretary

1300 889 838

investors@hsctg.com.au

More on HSC

[Investor centre](#)

[About Us](#)

[News](#)

About CardiacSense

CardiacSense is a digital health company that has developed CE approved best-in class, wrist-wearable sensor technology with the sensitivity and specificity required for medical diagnosis and monitoring of vital signs, arrhythmias, and chronic disease deterioration.

The medical watch integrates proprietary patent-protected sensors and software algorithms to provide continuous measurement of parameters such as core temperature, respiratory rate, blood pressure, oxygen saturation and heart rate at CE and FDA-mandated accuracies – providing an alternative to costly, complex and invasive devices. This addresses the increasing global demand for remote patient monitoring and tele-health.

CardiacSense was founded in 2009 and is headquartered at Caesarea, Israel. www.cardiacsense.com

About HSC Technology Group Ltd. (ASX: HSC)

HSC provides a suite of technology enabled care solutions to the aged and disability sectors across multiple verticals, including retirement living, residential aged care, home, and community settings to improve the quality of life, later in life.

HSC's Software as a Service (SaaS) data analytics platform Talius Smart Care combines smart sensors with AI machine learning (powered by CSIRO) that delivers automated actions. Talius links awareness, analysis, and action through one platform allowing the care model to move from spot check care to sense-respond care. Nursing staff can switch their focus from data collection to building a human connection. Most importantly, residents benefit from a new era of autonomy and dignity.

HSC helps protect and connect our elderly and people with disabilities with a scalable healthcare technology platform integrated with leading third-party providers to ensure end-to-end solutions for Connected Health.

- ❖ HSC Care
- ❖ HSC Home
- ❖ Talius

FORWARD LOOKING STATEMENTS

Certain statements contained in this ASX release, including information as to the future financial or operating performance of the Company and its projects, are forward looking statements. Such forward looking statements:

- (a) are necessarily based upon several estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant technical, business, economic, competitive, political, and social uncertainties and contingencies;*
- (b) involve known and unknown risks and uncertainties that could cause actual events or results to differ materially from estimated or anticipated events or results reflected in such forward looking statements; and*
- (c) may include, among other things, statements regarding estimates and assumptions in respect of prices, costs, results, and capital expenditure, and are or may be based on assumptions and estimates related to future technical, economic, market, political, social, and other conditions. The Company disclaims any intent or obligation to publicly update any forward-looking statements, whether because of new information, future events, or results or otherwise.*

The words "believe", "expect", "contracted", "anticipate", "indicate", "contemplate", "target", "plan", "intends", "continue", "budget", "estimate", "may", "will", "schedule", "planned" and similar expressions identify forward looking statements. All forward looking statements contained in this ASX release are qualified by the foregoing cautionary statements. Recipients are cautioned that forward looking statements are not guarantees of future performance and accordingly recipients are cautioned not to put undue reliance on forward looking statements due to the inherent uncertainty therein.